{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:32:15Z","timestamp":1772119935648,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s11906-019-0991-2","type":"journal-article","created":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T06:14:34Z","timestamp":1570688074000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Legacy Effect in the Treatment of Hypertension: Persistent Cardiovascular Protection after Conclusion of Randomized Clinical Trials in Hypertension"],"prefix":"10.1007","volume":"21","author":[{"given":"Giovanna","family":"Gallo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allegra","family":"Battistoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Coluccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliano","family":"Tocci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Volpe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,10]]},"reference":[{"issue":"9369","key":"991_CR1","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/S0140-6736(03)13302-8","volume":"361","author":"JA Staessen","year":"2003","unstructured":"Staessen JA, Wang J, Bianchi G, Birkenhager WH. Essential hypertension. Lancet. 2003;361(9369):1629\u201341.","journal-title":"Lancet."},{"issue":"9311","key":"991_CR2","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahlof","year":"2002","unstructured":"Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995\u20131003.","journal-title":"Lancet."},{"issue":"9364","key":"991_CR3","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"PS Sever","year":"2003","unstructured":"Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149\u201358.","journal-title":"Lancet."},{"issue":"9118","key":"991_CR4","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","volume":"351","author":"L Hansson","year":"1998","unstructured":"Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351(9118):1755\u201362.","journal-title":"Lancet."},{"issue":"9426","key":"991_CR5","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","volume":"363","author":"S Julius","year":"2004","unstructured":"Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022\u201331.","journal-title":"Lancet."},{"issue":"10022","key":"991_CR6","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957\u201367.","journal-title":"Lancet."},{"issue":"23","key":"991_CR7","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1093\/eurheartj\/ehq328","volume":"31","author":"S Bangalore","year":"2010","unstructured":"Bangalore S, Messerli FH, Wun CC, Zuckerman AL, DeMicco D, Kostis JB, et al. J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J. 2010 Dec;31(23):2897\u2013908.","journal-title":"Eur Heart J."},{"issue":"20","key":"991_CR8","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/j.jacc.2009.05.073","volume":"54","author":"FH Messerli","year":"2009","unstructured":"Messerli FH, Panjrath GS. The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? J Am Coll Cardiol. 2009;54(20):1827\u201334.","journal-title":"J Am Coll Cardiol."},{"issue":"7","key":"991_CR9","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","volume":"31","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281\u2013357.","journal-title":"J Hypertens."},{"issue":"19","key":"991_CR10","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","volume":"289","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560\u201372.","journal-title":"JAMA."},{"key":"991_CR11","unstructured":"\u2022 Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2017 Nov 13. US guidelines which have a major influence on diagnosis and treatment of hypertension in the USA and worldwide."},{"issue":"33","key":"991_CR12","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"\u2022 Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021\u2013104 European guidelines which have a major influence on diagnosis and treatment of hypertension in Europe and worldwide.","journal-title":"Eur Heart J"},{"key":"991_CR13","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ijcard.2017.12.026","volume":"254","author":"M Volpe","year":"2018","unstructured":"\u2022 Volpe M, Gallo G, Tocci G. Is early and fast blood pressure control important in hypertension management? Int J Cardiol. 2018;254:328\u201332 This review has systematically analyzed the benefits of an early achievement of BP control.","journal-title":"Int J Cardiol"},{"issue":"6","key":"991_CR14","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1161\/HYPERTENSIONAHA.110.160291","volume":"56","author":"WJ Kostis","year":"2010","unstructured":"Kostis WJ, Thijs L, Richart T, Kostis JB, Staessen JA. Persistence of mortality reduction after the end of randomized therapy in clinical trials of blood pressure-lowering medications. Hypertension. 2010;56(6):1060\u20138.","journal-title":"Hypertension."},{"issue":"22","key":"991_CR15","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr","year":"2015","unstructured":"\u2022 Group SR, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103\u201316 On the basis of the results of this trial, internaltional guidelines have reassessed new and more stringent BP goals to be achieved.","journal-title":"N Engl J Med"},{"issue":"9689","key":"991_CR16","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S0140-6736(09)61340-4","volume":"374","author":"P Verdecchia","year":"2009","unstructured":"Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet. 2009;374(9689):525\u201333.","journal-title":"Lancet."},{"issue":"2","key":"991_CR17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1161\/HYPERTENSIONAHA.109.146035","volume":"56","author":"T Ogihara","year":"2010","unstructured":"Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension. 2010;56(2):196\u2013202.","journal-title":"Hypertension."},{"key":"991_CR18","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.116.303641","volume":"116","author":"A Zanchetti","year":"2015","unstructured":"\u2022 Zanchetti A, Thomopoulos C, Parati G. Randomized controlled trials of blood pressure lowering in hypertension. a critical reappraisal. Circ Res. 2015;116:1058\u201373 This meta-analysis has demonstrated the benefits of BP lowering also in individuals with low-to-moderate risk.","journal-title":"Circ Res."},{"issue":"7152","key":"991_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1136\/bmj.317.7152.167","volume":"317","author":"OK Andersson","year":"1998","unstructured":"Andersson OK, Almgren T, Persson B, Samuelsson O, Hedner T, Wilhelmsen L. Survival in treated hypertension: follow up study after two decades. BMJ. 1998;317(7152):167\u201371.","journal-title":"BMJ."},{"issue":"4","key":"991_CR20","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s11906-011-0205-z","volume":"13","author":"M Volpe","year":"2011","unstructured":"Volpe M, Cosentino F, Tocci G, Palano F, Paneni F. Antihypertensive therapy in diabetes: the legacy effect and RAAS blockade. Curr Hypertens Rep. 2011;13(4):318\u201324.","journal-title":"Curr Hypertens Rep."},{"issue":"2","key":"991_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jacl.2011.01.006","volume":"5","author":"WJ Kostis","year":"2011","unstructured":"Kostis WJ, Moreyra AE, Cheng JQ, Dobrzynski JM, Kostis JB. Continuation of mortality reduction after the end of randomized therapy in clinical trials of lipid-lowering therapy. J Clin Lipidol. 2011;5(2):97\u2013104.","journal-title":"J Clin Lipidol."},{"issue":"11","key":"991_CR22","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1161\/CIRCULATIONAHA.115.019014","volume":"133","author":"I Ford","year":"2016","unstructured":"Ford I, Murray H, McCowan C, Packard CJ. Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of West of Scotland Coronary Prevention Study. Circulation. 2016;133(11):1073\u201380.","journal-title":"Circulation."},{"issue":"19","key":"991_CR23","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1161\/CIRCULATIONAHA.115.018580","volume":"133","author":"WE Hague","year":"2016","unstructured":"Hague WE, Simes J, Kirby A, Keech AC, White HD, Hunt D, et al. Long-term effectiveness and safety of pravastatin in patients with coronary heart disease: sixteen years of follow-up of the LIPID Study. Circulation. 2016;133(19):1851\u201360.","journal-title":"Circulation."},{"issue":"9315","key":"991_CR24","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/S0140-6736(02)08351-4","volume":"359","author":"Group LS","year":"2002","unstructured":"Group LS. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet. 2002;359(9315):1379\u201387.","journal-title":"Lancet."},{"issue":"8","key":"991_CR25","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/jch.12139","volume":"15","author":"KL Margolis","year":"2013","unstructured":"Margolis KL, Davis BR, Baimbridge C, Ciocon JO, Cuyjet AB, Dart RA, et al. Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). J Clin Hypertens (Greenwich). 2013;15(8):542\u201354.","journal-title":"J Clin Hypertens (Greenwich)."},{"issue":"23","key":"991_CR26","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1001\/jama.1979.03300230018021","volume":"242","author":"Five-year findings of the hypertension detection and follow-up program. I","year":"1979","unstructured":"\u2022\u2022 Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA. 1979;242(23):2562\u201371 This study has analyzed the long-term benefits on cardiovascular outcomes of antihypertensive treatment during an extended follow-up and it is of great relevance to investigate a potential legacy effect of BP-lowering therapy.","journal-title":"JAMA"},{"key":"991_CR27","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Persistence of reduction in blood pressure and mortality of participants in the Hypertension Detection and Follow-up Program. Hypertension Detection and Follow-up Program Cooperative Group. JAMA. 1988;259(14):2113\u201322 This study has analyzed the long-term benefits on cardiovascular outcomes of antihypertensive treatment during an extended follow-up and it is of great relevance to investigate a potential legacy effect of BP-lowering therapy.","DOI":"10.1001\/jama.259.14.2113"},{"issue":"15","key":"991_CR28","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJMoa0806359","volume":"359","author":"RR Holman","year":"2008","unstructured":"\u2022\u2022 Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008;359(15):1565\u201376 This study has analyzed the long-term benefits on cardiovascular outcomes of antihypertensive treatment during an extended follow-up and it is of great relevance to investigate a potential legacy effect of BP-lowering therapy.","journal-title":"N Engl J Med"},{"issue":"11","key":"991_CR29","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1097\/HJH.0000000000000709","volume":"33","author":"MR Nelson","year":"2015","unstructured":"\u2022\u2022 Nelson MR, Chowdhury EK, Doust J, Reid CM, Wing LM. Ten-year legacy effects of baseline blood pressure \u2018treatment naivety\u2019 in the Second Australian National Blood Pressure study. J Hypertens. 2015;33(11):2331\u20137 This study has analyzed the long-term benefits on cardiovascular outcomes of antihypertensive treatment during an extended follow-up and it is of great relevance to investigate a potential legacy effect of BP-lowering therapy.","journal-title":"J Hypertens"},{"issue":"1","key":"991_CR30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.amjcard.2004.08.059","volume":"95","author":"JB Kostis","year":"2005","unstructured":"\u2022\u2022 Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR, et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005;95(1):29\u201335 This study has analyzed the long-term benefits on cardiovascular outcomes of antihypertensive treatment during an extended follow-up and it is of great relevance to investigate a potential legacy effect of BP-lowering therapy.","journal-title":"Am J Cardiol"},{"issue":"9489","key":"991_CR31","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"B Dahlof","year":"2005","unstructured":"\u2022\u2022 Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005;366(9489):895\u2013906 This study has analyzed the long-term benefits on cardiovascular outcomes of antihypertensive treatment during an extended follow-up and it is of great relevance to investigate a potential legacy effect of BP-lowering therapy.","journal-title":"Lancet"},{"issue":"5","key":"991_CR32","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.2337\/diacare.28.5.1151","volume":"28","author":"PS Sever","year":"2005","unstructured":"Sever PS, Poulter NR, Dahlof B, Wedel H, Collins R, Beevers G, et al. Reduction in cardiovascular events with atorvastatin in 2532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care. 2005;28(5):1151\u20137.","journal-title":"Diabetes Care."},{"issue":"1","key":"991_CR33","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1751-7176.2011.00568.x","volume":"14","author":"WC Cushman","year":"2012","unstructured":"\u2022\u2022 Cushman WC, Davis BR, Pressel SL, Cutler JA, Einhorn PT, Ford CE, et al. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens (Greenwich). 2012;14(1):20\u201331 This study has analyzed the long-term benefits on cardiovascular outcomes of antihypertensive treatment during an extended follow-up and it is of great relevance to investigate a potential legacy effect of BP-lowering therapy.","journal-title":"J Clin Hypertens (Greenwich)"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-019-0991-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-019-0991-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-019-0991-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T19:40:30Z","timestamp":1602186030000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-019-0991-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,10]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["991"],"URL":"https:\/\/doi.org\/10.1007\/s11906-019-0991-2","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736743383.793578586","asserted-by":"object"}]},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,10]]},"assertion":[{"value":"10 October 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"85"}}